Publication
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Authors not recorded
J Immunother Cancer2021PMID 33653800PMC7929846stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerSolid Neoplasmcivic_curation1.00
- drugImmune Checkpoint Inhibitorcivic_curation1.00
- geneLRP1Bcivic_curation1.00
- variantLRP1B Loss-of-functioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 33653800
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| LRP1B Loss-of-function1 | ||||||||
| Immune Checkpoint Inhibitor | Solid NeoplasmCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID12252In this trial, 101 patients with solid tumours, including lung, prostate, sarcoma, melanoma, and breast cancer, harbouring LRP1B alterations were treated with immune checkpoint inhibitors. Most patien… (full text at CIViC) PMID 33653800 · Brown et al., 2021 · Open in CIViC | civic |